REGENXBIO Inc. (RGNX) Q4 2023 Earnings Call Transcript

REGENXBIO Inc. (NASDAQ:RGNX) Q4 2023 Earnings Conference Call February 27, 2024 4:30 PM ET

Company Participants

Patrick Christmas – Chief Legal Officer
Ken Mills – Chief Executive Officer
Steve Pakola – Chief Medical Officer
Vit Vasista – Chief Financial Officer

Conference Call Participants

Gena Wang – Barclays
Gospel Enyindah-Asonye – Morgan Stanley
Alec Stranahan – Bank of America
Annabel Samimy – Stifel
Lisa Walter – RBC Capital Markets
Mani Foroohar – Leerink Partners

Operator

Good day, and thank you for standing by. Welcome to REGENXBIO’s Fourth Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised today’s conference is being recorded.

I would now like to hand the conference over to Patrick Christmas, Chief Legal Officer. Please go ahead.

Patrick Christmas

Good afternoon, and thank you for joining us today. Earlier this afternoon, REGENXBIO released financial and operating results for the fourth quarter and full year ended December 31, 2023. The press release is available on our website at www.regenxbio.com.

Today’s conference call will include forward-looking statements regarding our financial outlook, in addition to regulatory and product development plans. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted and can be identified by words such as expect, plan, will, may, anticipate, believe, should, intend, and other words of similar meaning. Any such forward-looking statements are not guarantees of future performance and involve certain risks and uncertainties. These risks are described in the risk factors and the management’s discussion and analysis sections, REGENXBIO’s annual report on Form 10-K for the full year ended December 31, 2023, and comparable risk factors sections of REGENXBIO’s quarterly report on Form 10-Q, which are on file with the Securities and Exchange Commission and available on the SEC’s website.